Daniel I. Simon, MD

Daniel I. Simon, MD

Chief Clinical & Scientific Officer, University Hospitals Health System President, UH Cleveland Medical Center
Daniel I. Simon, MD


Dan Simon, MD is Chief Clinical & Scientific Officer for the University Hospitals Health System (UH) and the President of UH Cleveland Medical Center. He is also Professor of Medicine at Case Western Reserve University School of Medicine, affiliated with UH.

As Chief Clinical & Scientific Officer, Dr. Simon leads UH’s 14 clinical care delivery institutes and manages all UH clinical department chairs. He is also charged with shaping a new approach to UH’s academic mission in a changing and challenging environment for academic medical centers nationally. Additionally, Dr. Simon oversees the region’s only freestanding cancer hospital: UH Seidman Cancer Center; the internationally renowned UH Rainbow Babies & Children’s Hospital; and Harrington Discovery Institute at University Hospitals -- part of The Harrington Project for Discovery & Development.

As President of UH Cleveland Medical Center, Dr. Simon is responsible for developing, implementing and evaluating clinical and safety standards and practice for the academic medical center. Additionally, he provides oversight for the full spectrum of research activities spanning basic/translational research to clinical and population research as well as graduate medical education, continuing medical education, undergraduate medical education and community education.

Dr. Simon joined UH in 2006 as Division Chief of Cardiovascular Medicine at UH Cleveland Medical Center and as Director of the UH Harrington Heart & Vascular Institute. In 2016, he was promoted to President of UH Cleveland Medical Center and in 2018, he became Chief Academic Officer for the entire health system and assumed leadership for all UH community hospitals. Dr. Simon is an active interventional cardiologist and continues to play a leading role in national and international clinical trials investigating new devices, antithrombotic drugs, and regenerative medicine therapies.

Prior to UH, Dr. Simon served as Associate Director of Interventional Cardiology at Brigham and Women’s Hospital in Boston and was an Associate Professor of Medicine at Harvard Medical School.

A recipient of numerous research awards, Dr. Simon was elected into the American Society for Clinical Investigation, Association of University Cardiologists, and the Association of American Physicians. He is a recipient of the prestigious MERIT Award from the National Heart, Lung,

and Blood Institute and the 2016 Distinguished Scientist Award from the American College of Cardiology. He is a Fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiac Angiography and Interventions.

He has published extensively in peer-reviewed basic science and clinical journals. Dr. Simon has served on the Editorial Boards of Circulation and Journal American College Cardiology and was recently appointed to the Editorial Board of JAMA Cardiology.

He graduated summa cum laude from Harvard College. After earning his medical degree from Harvard Medical School, he completed his internal medicine residency and cardiovascular medicine fellowship at Brigham and Women’s Hospital and interventional cardiology training at Beth Israel Hospital, Harvard Medical School.

Dr. Simon is the Co-Founder of Sujana Biotech, a start-up biotechnology company developing novel monoclonal antibodies for a range of inflammatory and vascular disorders. The company’s lead product is in the early preclinical phase of development.

Dr. Simon serves on the Board of Directors of Playhouse Square and University Circle Inc.